Josephine van Dongen

3 Updated cost-effectiveness and risk-benefit analysis 73 Acknowledgements We thankWilfrid van Pelt for providing historical data on rotavirus detections in the Netherlands from virological surveillance. Funding PB-V has received funding from the Netherlands Organization for Health Research and Development for conduct of the RotaFam study (ZonMw number 016.166.158) and Risk- Group Infant Vaccination Against Rotavirus (RIVAR) study (ZonMw number 80–83600–98- 20129).